Suven Life secures new patents in Canada, Hong Kong
10 Apr 2014
Suven Life Sciences Ltd has obtained two new patents, one each from Hong Kong and Canada, for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company that were being developed as therapeutic agents.
They were useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinsons and schizophrenia.
Suven said the product patents from Hong Kong (HK 1133002) and Canada (CA 2737282) corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, are valid through 2023 and 2029, respectively.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,'' Venkat Jasti, CEO of Suven, said.
With these new patents, Suven has a total of 15 patents from Canada and 14 product patents from Hong Kong.
''These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,'' the company said.
Suven Life Sciences Ltd (Suven) today announced the receipt of one product patent from Hong Kong (HK 1133002) and one product patent from Canada (CA 2737282) corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
Suven said these patents are valid through 2023 and 2029 respectively.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
The company has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
